Dr. Martin graduated from Duke University School of Medicine and completed post graduate clinical training in Internal Medicine. He spent 3 years of research at the National Institutes of Health (NIH) and then migrated to UCSF as an Assistant Professor in Medicine and Biochemistry. After 13 years, Dr. Martin joined Genentech as the founding head of Research and Development for 8 years before moving to DuPont-Merck as founding head of R&D of the new joint venture in Delaware.
After returning to the SF Bay Area at Chiron, Dr. Martin has remained in the biotech field, starting and managing numerous companies until "retiring" and migrating back to the RDU area of North Carolina. He resides in Chapel Hill and is active on 3 for-profit and 3 not-for-profit entities.
Dr. Parmar is a Managing Partner at 5AM Ventures. He serves as a Director of the Boards of Ensoma, Entrada (NASDAQ: TRDA), GlycoEra, Precede Bioscience, and Rallybio (NASDAQ: RLYB). Dr. Parmar serves as Board Member or Observer for Achaogen (NASDAQ: AKAO), Akouos (acquired by Eli Lilly), Arvinas (NASDAQ: ARVN), Audentes (acquired by Astellas), Envoy (acquired by Takeda), Homology (NASDAQ: FIXX), scPharmaceuticals (NASDAQ: SCPH) and Vor Biopharma (NASDAQ: VOR) and as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J).
Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University's Departnent of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows.
Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massacheusetts General & Brigham and Women's Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
Dr. Santi received a Ph.D. in Medicinal Chemistry from SUNY in 1967 and a M.D. from UCSF in 1981. He was Assistant Professor of Chemistry at UCSF from 1968 to 1974. He joined the UCSF faculty in 1974 and was Professor of Biochemistry and Biophysics, and of Pharmaceutical Chemistry at UCSF until 2000 when he became CEO of Kosan Biosciences. He returned to UCSF in 2007 where he served as interim Director of the Clinical and Translational Science Institute and then Director of Translational Research at QB3. He was Associate Dean for External Relationships in the SOP from 2009-2019 and managed a successful Industry Outreach Program. Dr. Santi has published over 325 scientific papers and is co-inventor on over 40 US Patents.
Dan Santi was a member of the original Scientific Advisory Board of Chiron Corp. and has co-founded five biotechnology companies In 1988, he founded and was Chairman of the peptide-combinatorial chemistry company Protos Corp., which merged with Chiron in 1992. He was a co-founder of Parnassus Pharmaceuticals, and of Prospect Genomics that merged with Structural Genomix in 2001. In 1996, he co-founded Kosan Biosciences where he served as CEO and Chairman until 2006; Kosan was acquired by Bristol Myers Squibb. During his tenure as CEO the company went public (NASDAQ), and found oncology compounds were brought into clinical trials. He co-founded the platform technology company ProLynx, where he currently serves as President.
Dr. Thompson joined Orbimed in 2010 and is a General Partner of Orbimed. He has over 25 years of industry experience. Dr. Thompson held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded several OrbiMed portfolio companies, and serves as a Director on many portfolio company boards. He was on staff at the National Cancer Institute following his internal medicine training at Yale University. Dr. Thompson earned his bachelor's degree in Molecular Biology and Mathematics as well as his medical degree from Brown University.
Dr. Cohen is a Founder and member of the Investment Committee of Monograph, which he co-founded in 2021. Prior to Monograph, he was Co-Founder and Senior Managing Director of Vida Ventures and Managing Partner at TPG Biotechnology, where he initiated TPG's venture efforts in biotechnology and life sciences in 2001.
Earlier, Dr. Cohen was a Professor, where he served as Chief of the Division of Endocrinology and Metabolism and led research in prionbiology, drug design, bioinformatics, and heteropolymer chemistry. He is a member of the National Academy of Medicine, the American Academy Arts and Sciences, and a fellow of the American College of Physicians. Dr. Cohen has received several awards, including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L'Art Prize, and the Searle Scholars Award. He graduated magna cum laude from Yale University in 1978, received his D.Phil. from Oxford University as a Rhodes Scholar in 1980, earned his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and completed his internal medicine and endocrinology training at UCSF.